These findings indicated that SGLT2 inhibitors can lower serum asprosin levels and improve glucolipid and weight in patients with newly diagnosed T2DM, which may benefit the cardiovascular system. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.